Skip to main content

GenetiSure Dx Postnatal Assay Clinical Studies

GenetiSure DX banner

The GenetiSure Dx Postnatal Assay has been validated and tested extensively. Below is a summary of the studies performed on the assay.

      • The analytical-accuracy study demonstrated the accuracy of the GenetiSure Dx Postnatal Assay using a panel of approximately 600 samples from different sources that exhibited aberrations across the entire genome. The average confirmation rates were 93.5% for larger CNVs (>20 probes) and 92.5% for small CNVs (5 to 20 probes). For cnLOH intervals, the average confirmation rate was 90.1%. The confirmation rate (%) is the number of assay-identified aberrations confirmed using a reference method divided by the total number of the assay-identified aberrations.

      • The GenetiSure Dx Postnatal Assay, which included 900 samples, was validated in a clinical study involving several partner laboratories. The study demonstrated that the assay has clinical validity and diagnostic utility, as compared to standard-of-care methods. The diagnostic yield for the assay, when considering only CNVs, was 15%, which was comparable to the diagnostic yield obtained for the same samples at the collection sites using non-Agilent microarray methods. This yield increased to 20% when cnLOH aberrations were also considered, exceeding the diagnostic yield at the collection sites.

      • To determine the analytical sensitivity, or Limit of Detection (LOD), of the GenetiSure Dx Postnatal Assay, a study was conducted to evaluate the minimum and maximum amounts of DNA acceptable as the assay input. Results support the use of 500 ng as the recommended input amount. The data demonstrated that performance did not decline down to 375 ng. For CNVs only, the LOD could be further reduced to 250 ng.

      • The results of this study demonstrated that the GenetiSure Dx Postnatal Assay was reproducible when performed at multiple laboratory sites by different operators over multiple days and is suitable for implementation in a clinical laboratory environment.

      • The results of the precision study demonstrated that assay results are not affected by multiple extractions of the same sample, multiple reagent lots or scanners.

      • The presence of contamination could result in corrupt and inaccurate patient data. This study was designed to determine whether cross contamination occurs during the routine assay workflow, and if so, what the impact on data would be. No suspected cross contamination was detected.

      • Whole blood specimens from the collection site may be stored prior to processing, or they may need to be transferred to a remote laboratory for processing; therefore, a whole blood stability study was performed. Whole blood specimens stored for up to 10 days at 2°C to 8°C prior to gDNA isolation, and then processed with the GenetiSure Dx Postnatal Assay, produced acceptable results.

      • The GenetiSure Dx Postnatal Assay uses gDNA isolated from patient whole blood. Specimens may be obtained from patients with endogenous conditions resulting in hemolysis, bilirubinemia or lipemia. An interfering study was performed to determine the effects of these conditions on the results of the test. The study demonstrated that the assay results are not altered by the presence of excessive hemoglobin, triglycerides (triolein) or bilirubin (conjugated or unconjugated) in the patient whole blood specimen.

Continue to

User Portal

For more information, please visit

INTENDED USE: GenetiSure Dx Postnatal Assay is a qualitative assay intended for the postnatal detection of copy-number variations (CNV) and copy-neutral loss of heterozygosity (cnLOH) in genomic DNA obtained from peripheral whole blood in patients referred for chromosomal testing based on clinical presentation. GenetiSure Dx Postnatal Assay is intended for the detection of CNVs and cnLOH associated with developmental delay, intellectual disability, congenital anomalies or dysmorphic features. Assay results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including confirmation by alternative methods, parental evaluation, clinical genetic evaluation and counseling, as appropriate. Interpretation of assay results is intended to be performed only by healthcare professionals who are board-certified in clinical cytogenetics or molecular genetics.

The assay is intended to be used on the SureScan Dx Microarray Scanner System and analyzed by CytoDx Software.

WARNING: This device is not intended to be used for standalone or diagnostic purposes, pre-implantation or prenatal testing or screening, population screening or the detection of, or screening for, acquired or somatic genetic aberrations.

The products referenced on this page are not available for sale in all countries or jurisdictions. The information contained in this website may not be valid in your jurisdictions. Please contact your local sales representative for additional information.


Related Information